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OBJECTIVES: Cutaneous malignant melanoma (MCM) is a
major concern for health care providers and its incidence is
increasing. We systematically reviewed published articles
describing the impact on quality-of-life (QOL) of drugs for
MCM management, and all available economic analyses that
focused on this disease. METHODS: We searched secondary
databases including Medline, Embase, CINAHL, Cochrane, and
DARE from inception to 2006 using MESH terms “melanoma”
and “metastases”. Results were then combined with terms con-
cerning economic analyses (i.e., cost analysis, cost beneﬁt analy-
sis, cost control, cost savings, cost of illness, etc.), and quality of
life studies (i.e., quality adjusted life years, health status, QOL,
and QALY). Economic articles were assessed for quality utiliz-
ing the scale described by Iskedjian et al. RESULTS: Our search
strategy found 7 economic and 13 QOL studies. Economic
studies comprised 4 cost-effective analyses (CEAs), 2 burden of
illness studies (COIs), and 1 cost-utility analysis (CUA). All eco-
nomic studies scored >80% in quality. No strong evidence was
presented for cost-effectiveness of interferons in UK or Canada,
or for temazolomide in US. Screening for melanoma was not
cost-effective in US or Germany. Cost studies found the major-
ity of costs (90%) accrued in Stages 3&4. From the 13 QOL
studies, 8 measured baseline QOL, 6 of which studied the same
population, and generated similar results but with different
approaches (i.e., outcome measures). Tools used included GLQ-
8, QLQ-C30, QLQ-36, QWB-SA, and SF-36. Baseline scores
QOL scores ranged from 0.60–0.69. Another 5 studies (N = 959
patients) were randomized trials analyzing QOL in patients
treated with DTIC alone, DTIC ± interferon, DTIC + fotemus-
tine, interleukin ± histamine, and temozolomide. Little difference
was found in QOL scores between drugs or between baseline
and endpoint. CONCLUSIONS: Costs are substantial. Cost-
effectiveness has not been shown for screening or treatment of
MCM. Generally, no signiﬁcant improvements in QOL were
found for any alternative for treating MCM.
PCN64
DIFFERENTIAL ITEM FUNCTIONING USING RASCH ANALYSIS
Brodersen J,Thorsen H
University of Copenhagen, Copenhagen, Denmark
OBJECTIVES: The aim of the study was to test items for Dif-
ferential Item Functioning (DIF) in a condition-speciﬁc measure
for women having an abnormal screening mammography.
METHODS: The draft version of a 33-item condition-speciﬁc
measure was completed by 184 women who had received an
abnormal screening mammography and two weeks later by the
same women after having either a known false-positive result, a
diagnosed breast cancer or still undiagnosed. The measure was
also completed by 240 women with a normal screening result.
Data were analysed using the Rasch model. DIF relative to
person covariates was checked by analyses of variance examin-
ing the degree to which individual residuals for speciﬁc items
depended on the covariates. Absence of evidence of interaction
between the covariates and the estimated trait parameters were
taken as evidence of DIF being uniform. If uniform DIF was iden-
tiﬁed; mean scores of the dimension were estimated from the
means of the person locations on the latent trait according to
DIF found. RESULTS: One of six items in a dimension measur-
ing “sense of dejection” had uniform DIF in two of four sub-
groups. After deleting this item the remaining items still ﬁtted
the Rasch model with no DIF. In a 2-item dimension describing
the impact on breast examination both items had uniform DIF.
The ﬁrst item had uniform DIF relative to women diagnosed with
breast cancer and the second item had uniform DIF relative to
women with normal screening mammography. There was dif-
ference in the mean of the subscales’ raw score and the estimated
scores calculated according to identiﬁed DIF. CONCLUSION: If
an item functions differently in subpopulations and it is decided
to keep the item in a subscale; special precautions should be
taken when calculating scores of this dimension. Otherwise, 
the difference between subpopulations could be under or 
overestimated.
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ADHERENCE IN CANCER PATIENTS RECEIVING ORAL
CAPECITABINE
Roth S1, Simons S1,Arjukese A1, Braun M1, Ko Y2, Kuhn W1, Mey U1,
Schwindt P3,Wolter H3, Jaehde U1
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OBJECTIVES: Capecitabine is an orally administered prodrug
of ﬂuorouracil, which is used for the treatment of colorectal and
breast cancer patients. Since patients take this drug usually at
home a high adherence to the prescribed dosage regimen is a
major prerequisite for therapeutic efﬁcacy. METHODS: Adher-
ence to capecitabine chemotherapy was assessed using
MEMS(TM)-vials. The closures of the vials are equipped with
an integrated micro-electronic circuit registering every opening
and closing. With the corresponding software the medication
events of the particular patient can be displayed on a computer
and evaluated. Percentage of correctly administered doses of
medication (i.e. registered openings of the MEMS(TM)-vial at
the correct time), and dosage (i.e. opening) intervals were deﬁned
as main outcome measures. RESULTS: We assessed the adher-
ence to capecitabine chemotherapy (taken twice daily for 14 days
with a 7 days break between the cycles) in 20 patients (14 breast
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